
18 May 2026: SonoMind raised a €20M Series A led by Critical Path Ventures and Bpifrance, following a €3M seed in 2025. The Paris company uses low-intensity focused ultrasound, steered through a patient-specific acoustic lens, to treat treatment-resistant depression. Early work at Hôpital Sainte-Anne reported a 60% reduction in symptoms after five days of one-hour sessions. SonoMind targets market authorisation around 2029. Read our coverage.
The French startup raised a €20M Series A led by Critical Path Ventures and Bpifrance to fund clinical trials of its focused ultrasound treatment for treatment-resistant depression. SonoMind uses a patient-specific acoustic meta-lens to direct low-intensity ultrasound toward deep brain structures that TMS and tDCS cannot easily reach. Preliminary results from Sainte-Anne Hospital showed more than 60% reduction in symptom severity after five consecutive daily sessions; market authorization is targeted by 2029.